| Quarterly Financials | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 978 | 1,188 | 1,093 | 955 | 1,026 | 1,050 | 1,030 | 1,081 | 1,051 | 1,050 |
| Expenses | 1,095 | 1,057 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 |
| EBITDA | -117 | 131 | 103 | 14 | 135 | 138 | 141 | 120 | 156 | 127 |
| Operating Profit % | -13 % | 11 % | 9 % | 0 % | 13 % | 12 % | 12 % | 9 % | 13 % | 9 % |
| Depreciation | 30 | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 |
| Interest | 12 | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 |
| Profit Before Tax | -159 | 87 | 59 | -33 | 88 | 92 | 91 | 75 | 96 | 66 |
| Tax | 29 | 54 | -136 | 7 | 26 | 25 | 25 | -75 | 31 | 23 |
| Net Profit | -187 | 33 | 195 | -40 | 61 | 67 | 66 | 150 | 65 | 43 |
| EPS in ₹ | -13.16 | 2.22 | 13.21 | -2.89 | 4.21 | 4.37 | 4.26 | 9.64 | 4.15 | 2.66 |
Akums Drugs & Pharma
Akums Drugs & Pharma
428.00
+8.50
(2.03%)
Market Cap
₹6,736.46 Cr
PE Ratio
20.54
Volume
1,03,658.00
Day High - Low
₹432.00 - ₹417.75
52W High-Low
₹678.40 - ₹405.00
Key Fundamentals
Market Cap
6,736.46 Cr
EPS
22.60
PB Ratio
2.11
Book Value
200.11
EBITDA
516.60
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
0.17
Analyst Rating and Forecast
- By Refinitiv from3 analysts
Actual
Company News
View All News
Akums Drugs Q2FY26 Earnings: Revenue Flat at INR 1,018 Crores, EBITDA Margins Drop to 9.3%
10 days ago
10 days agoAkums Drugs reported flat quarterly results with revenue at INR 1,018 crores (down 1.5% year-on-year) and EBITDA margins declining to 9.3% from 11.7% in Q2FY25, impacted by continued API price declines of 8% and higher overheads from new facilities. The company announced a joint venture with Zambia government for a USD 45 million manufacturing plant and secured European CDMO contract approvals, with commercial supplies to Europe expected from 2027.
Akums Drugs Fully Utilizes Rs 6,373.70 Million IPO Proceeds Across All Stated ObjectivesNov 15, 2025
Akums Drugs and Pharmaceuticals Limited has completely utilized its IPO proceeds of Rs 6,373.70 million across five key areas including debt repayment (Rs 3,870 million), working capital funding (Rs 550 million), inorganic growth initiatives (Rs 278.70 million), and general corporate purposes (Rs 1,675 million). CRISIL Ratings Limited's monitoring report for the quarter ended September 30, 2025, confirms no deviations from the original objectives stated in the offer document, with all funds deployed as planned between September 2024 and June 2025.
Akums Drugs and Pharmaceuticals approved quarterly results for the quarter and half year ended 30 September 2025, alongside designating two senior management personnel including Dr. Shantanu Rajaram Chobhe as President (CQA) Formulation and Mr. Vinayak Bhat as VP (Operations) API division. The company's board approved a USD 24 million investment in Akums Healthcare (Zambia) Private Limited to establish manufacturing facilities and expand operations in the Zambian market and neighboring African countries, with the investment to be made in a staggered manner through March 2028.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,820.60 | #1 4,36,822.92 | 40.68 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 76.30 | |
6,490.00 | 1,72,289.11 | 69.05 | 9,712.00 | 18.67 | 2,191 | 35.10 | 50.50 | |
3,713.00 | 1,25,664.79 | 58.80 | 11,539.40 | 6.99 | 1,911 | 30.46 | 54.46 | |
1,525.00 | 1,23,182.50 | 22.73 | 28,409.50 | 7.12 | 5,291 | 3.71 | 48.61 | |
1,247.90 | 1,04,151.45 | #1 18.15 | 33,741.20 | 16.73 | 5,725 | -0.38 | 53.75 | |
2,081.40 | 95,068.89 | 21.34 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 63.44 | |
943.35 | 94,923.08 | 18.56 | 23,511.00 | 18.55 | 4,615 | 34.60 | 41.16 | |
2,245.00 | 92,664.28 | 52.05 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 38.34 | |
1,233.30 | 71,630.26 | 20.70 | 32,345.60 | 9.43 | 3,484 | 3.81 | 67.24 | |
5,691.50 | 68,050.42 | 28.29 | 13,458.30 | 3.70 | 2,216 | 10.98 | 53.98 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-0.99 %
Net Income Growth
42,875.00 %
Cash Flow Change
-6.64 %
ROE
10,100.00 %
ROCE
5,030.43 %
EBITDA Margin (Avg.)
232.17 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 2,078 | 2,192 | 3,069 | 3,267 | 3,516 | 4,113 |
| Fixed Assets | 645 | 834 | 1,021 | 1,097 | 1,191 | 1,397 |
| Current Assets | 1,250 | 1,157 | 1,864 | 1,879 | 1,941 | 2,275 |
| Capital Work in Progress | 57 | 87 | 31 | 103 | 195 | 163 |
| Investments | 6 | 19 | 0 | 0 | 0 | 0 |
| Other Assets | 1,371 | 1,252 | 2,017 | 2,066 | 2,130 | 2,553 |
| Total Liabilities | 2,078 | 2,192 | 3,069 | 3,267 | 3,516 | 4,113 |
| Current Liabilities | 730 | 580 | 1,272 | 1,266 | 1,211 | 894 |
| Non Current Liabilities | 627 | 725 | 1,172 | 1,278 | 1,585 | 156 |
| Total Equity | 721 | 887 | 625 | 723 | 721 | 3,064 |
| Reserve & Surplus | 721 | 884 | 608 | 689 | 681 | 3,016 |
| Share Capital | 1 | 1 | 14 | 29 | 29 | 31 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -11 | 4 | 71 | -70 | 33 | -4 | 59 | -10 |
| Investing Activities | -150 | -123 | -190 | -109 | -235 | -305 | -331 | -548 |
| Operating Activities | 72 | 89 | 28 | 135 | 32 | 177 | 498 | 465 |
| Financing Activities | 66 | 37 | 233 | -95 | 236 | 125 | -108 | 73 |
Share Holding
| % Holding | Feb 2024 | Aug 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 84.91 % | 75.26 % | 75.26 % | 75.26 % | 75.26 % | 75.26 % | 75.26 % |
| FIIs | 0.00 % | 5.32 % | 7.34 % | 6.36 % | 5.77 % | 4.24 % | 2.28 % |
| DIIs | 0.00 % | 7.60 % | 7.52 % | 7.00 % | 7.40 % | 8.85 % | 9.28 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 4.43 % | 2.11 % | 3.33 % | 3.41 % | 3.60 % | 5.01 % |
| Others | 15.09 % | 7.38 % | 7.77 % | 8.05 % | 8.16 % | 8.05 % | 8.18 % |
| No of Share Holders | 8 | 1,38,205 | 57,531 | 68,410 | 69,366 | 69,424 | 75,365 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 09 Nov 2024 |  Quarterly Result Announcement | NA | 09 Nov 2024 | 845.30 | 796.60 |
| 06 Feb 2025 | Quarterly Result Announcement | NA | 06 Feb 2025 | 566.55 | 570.30 |
| 26 May 2025 | Quarterly Result Announcement | NA | 26 May 2025 | 546.50 | 566.05 |
| 18 Jul 2025 |  Annual General Meeting | NA | 18 Jul 2025 | 566.05 | 559.90 |
| 08 Aug 2025 | Quarterly Result Announcement | NA | 08 Aug 2025 | 513.90 | 490.80 |
| 13 Nov 2025 | Quarterly Result Announcement | NA | 13 Nov 2025 | 454.45 | 453.15 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Monitoring Agency ReportNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2025
Nov 14, 2025UpdateNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 13, 2025
Nov 13, 2025Outcome Of Board MeetingNov 13, 2025
Nov 13, 2025Board Meeting Outcome for Outcome Of Board MeetingNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 10, 2025
Nov 10, 2025Board Meeting Intimation for Consider And Approve The Un-Audited (Standalone & Consolidated) Financial Results For The Quarter And Half Year Ended On 30Th September 2025Nov 08, 2025
Nov 08, 2025Grant Of PatentNov 03, 2025
Nov 03, 2025Incorporation Of Wholly Owned Subsidiary In MaltaOct 20, 2025
Oct 20, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Oct 14, 2025Incorporation Of Joint Venture CompanyOct 13, 2025
Oct 13, 2025Resignation Of Senior Management PersonnelOct 10, 2025
Oct 10, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 17, 2025
Sep 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 26, 2025
Aug 26, 2025Execution Of Framework Agreement With Government Of The Republic Of ZambiaAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 18, 2025
Aug 18, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Aug 09, 2025Board Comments On Fine Levied By The ExchangeAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 08, 2025
Aug 08, 2025Outcome Along With ResultsAug 08, 2025
Aug 08, 2025Board Meeting Outcome for Outcome Of Board MeetingAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Aug 05, 2025Board Meeting Intimation for Approval Of Un-Audited (Standalone & Consolidated) Financial Results For The Quarter Ended On 30Th June 2025.Aug 04, 2025
Aug 04, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 19, 2025
Jul 19, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Jul 14, 2025Resignation Of Senior Management PersonnelJul 05, 2025
Jul 05, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 25, 2025
Jun 25, 2025Business Responsibility and Sustainability Reporting (BRSR)Jun 24, 2025
Jun 24, 2025Reg. 34 (1) Annual Report.Jun 24, 2025
Jun 24, 2025Notice Convening 21St Annual General Meeting And Integrated Annual Report Of Financial Year 2024-25Jun 24, 2025
Jun 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 18, 2025
Jun 18, 2025The Company Is Hosting Plant Visit For InvestorsJun 16, 2025
Jun 16, 2025Intimation Of Approval Of Revised Notice Of Annual General Meeting (AGM)Jun 07, 2025
Jun 07, 2025Intimation Of Appointment Of Additional Director (Non-Executive- Independent)Jun 04, 2025
Jun 04, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 27, 2025
May 27, 2025Mutual Fund Holdings
Bandhan Small Cap Fund Direct-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
SBI Nifty 500 Index Fund Direct-Growth 
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth 
Kotak Nifty Smallcap 250 Index Fund Direct-Growth 
Groww Nifty Smallcap 250 Index Fund Direct - Growth 
Axis Nifty 500 Index Fund Direct-Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Mirae Asset Nifty Total Market Index Fund Direct-Growth 
JM Small Cap Fund Direct - Growth 
Aditya Birla Sun Life Balanced Advantage Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 38.90
ATR(14)
Less Volatile 13.60
STOCH(9,6)
Neutral 22.37
STOCH RSI(14)
Neutral 48.19
MACD(12,26)
Bearish -1.45
ADX(14)
Weak Trend 15.91
UO(9)
Bearish 44.63
ROC(12)
Downtrend And Accelerating -4.35
WillR(14)
Oversold -82.66
About Akums Drugs & Pharma
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) established in 2004. The company offers a wide range of pharmaceutical products and services both domestically and internationally. Their operations include manufacturing of Active Pharmaceutical Ingredients (APIs), sale of branded pharmaceutical formulations, formulation research and development, regulatory dossier preparation and filing, and testing services. Akums has manufacturing units accredited by global regulatory agencies and specializes in various therapeutic areas. The company has expanded through acquisitions and establishment of new facilities over the years. It operates in three main segments: CDMO, API, and Branded and Generic formulations. Akums has manufactured over 4,000 commercialized formulations across more than 60 dosage forms.
Listing Date
06 Aug, 2024(1 Years,
22 days)
Website
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
